Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Julphar
Cantor Fitzgerald
Teva
Medtronic
Accenture
Deloitte
UBS
Chubb

Generated: October 22, 2018

DrugPatentWatch Database Preview

Galen Uk Company Profile

« Back to Dashboard

What is the competitive landscape for GALEN UK , and what generic alternatives to GALEN UK drugs are available?

GALEN UK has one approved drug.

There are eighteen US patents protecting GALEN UK drugs.

Summary for Galen Uk
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Galen Uk

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 8,235,037 ➤ Try a Free Trial Y ➤ Try a Free Trial
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 8,173,107 ➤ Try a Free Trial Y ➤ Try a Free Trial
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,601,337 ➤ Try a Free Trial Y ➤ Try a Free Trial
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 9,439,907 ➤ Try a Free Trial Y ➤ Try a Free Trial
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 9,687,487 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 8,074,644 ➤ Try a Free Trial Y ➤ Try a Free Trial
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 6,716,416 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Galen Uk Drugs

Supplementary Protection Certificates for Galen Uk Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0609 Netherlands ➤ Try a Free Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
2013 00046 Denmark ➤ Try a Free Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
3 Finland ➤ Try a Free Trial
2013 00046 Denmark ➤ Try a Free Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
00609 Netherlands ➤ Try a Free Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
90040-2 Sweden ➤ Try a Free Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Citi
Moodys
Cipla
Dow
McKinsey
US Department of Justice
Fish and Richardson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.